Needle-free delivery of DNA: Targeting of hemagglutinin to MHC class II molecules protects rhesus macaques against H1N1 influenza.

Autor: Mooij P; Biomedical Primate Research Centre, Rijswijk, the Netherlands., Grødeland G; K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, N-0027 Oslo, Norway. Electronic address: gunnveig.grodeland@medisin.uio.no., Koopman G; Biomedical Primate Research Centre, Rijswijk, the Netherlands., Andersen TK; K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, N-0027 Oslo, Norway., Mortier D; Biomedical Primate Research Centre, Rijswijk, the Netherlands., Nieuwenhuis IG; Biomedical Primate Research Centre, Rijswijk, the Netherlands., Verschoor EJ; Biomedical Primate Research Centre, Rijswijk, the Netherlands., Fagrouch Z; Biomedical Primate Research Centre, Rijswijk, the Netherlands., Bogers WM; Biomedical Primate Research Centre, Rijswijk, the Netherlands., Bogen B; K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, N-0027 Oslo, Norway.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2019 Feb 04; Vol. 37 (6), pp. 817-826. Date of Electronic Publication: 2019 Jan 09.
DOI: 10.1016/j.vaccine.2018.12.049
Abstrakt: Conventional influenza vaccines are hampered by slow and limited production capabilities, whereas DNA vaccines can be rapidly produced for global coverage in the event of an emerging pandemic. However, a drawback of DNA vaccines is their generally low immunogenicity in non-human primates and humans. We have previously demonstrated that targeting of influenza hemagglutinin to human HLA class II molecules can increase antibody responses in larger animals such as ferrets and pigs. Here, we extend these observations by immunizing non-human primates (rhesus macaques) with a DNA vaccine encoding a bivalent fusion protein that targets influenza virus hemagglutinin (HA) to Mamu class II molecules. Such immunization induced neutralizing antibodies and antigen-specific T cells. The DNA was delivered by pain- and needle-free jet injections intradermally. No adverse effects were observed. Most importantly, the immunized rhesus macaques were protected against a challenge with influenza virus.
(Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: